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Abstract 
Kidney volume growth is considered the best surrogate parameter to predict renal function 
decline in autosomal dominant polycystic kidney disease . To assess the therapeutic benefit of 
novel drugs more rapidly, kidney volume changes need to be assessed in a short time interval. 
We hypothesized that renal volume changes can be measured within 6 months using 
unenhanced magnetic resonance imaging  and a manual segmentation method. One hundred 
patients affected by autosomal dominant polycystic kidney disease (37% females) with a 
mean (SD) age of 31.2±6.4 yr and creatinine clearance of 109.8±25.5 ml/min had a total 
kidney volume of 1003±568 cm3 at baseline which increased by 31.8±72.0 cm3 (2.71±4.82%) 
in 6 months (P<0.001). The total cyst volume was 476±440 cm3 at baseline and increased by 
32.8±92.5 cm3 (5.45±14.28%; P<0.001). Volume measurements were highly reproducible and 
accurate, as indicated by a concordance correlation coefficient (95% CI) of 1.000 (0.999-
1.000) for intraobserver and 0.996 (0.995-0.999) for interobserver agreement and a within-
subject standard deviation of 6.130 cm3 and 8.003 cm3, respectively. The change in renal 
volume correlated with baseline total kidney volume in all age subgroups. Total kidney 
volume correlated positively with male sex, hypertension, albuminuria and history of 
macrohematuria and negatively with creatinine clearance. Albuminuria was associated with 
accelerated volume progression. We conclude that kidney volume progression can be 
determined over a period as short as 6 months on unenhanced magnetic resonance imaging 
sequences in early autosomal dominant polycystic kidney disease.  
 
Key words: Autosomal dominant polycystic kidney disease (ADPKD), kidney volume, 
magnetic resonance imaging (MRI), volumetry 
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Introduction 
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the 
development of innumerable cysts which originate from the tubular epithelium of the 
nephrons.1 The disease affects all ethnic groups worldwide with an incidence of 1:500 to 
1:1000.2 The continuous growth of cysts leads to progressive kidney enlargement and 
subsequently to a loss of renal function.3 Currently specific treatment for ADPKD other than 
supportive care does not exist, but clinical trials have recently been initiated to examine the 
efficacy of various drugs in ADPKD, including the mTOR inhibitors sirolimus (rapamycin) 
and everolimus, the vasopressin V2 receptor antagonist tolvaptan, the somatostatin analogue 
octreotide-LAR and combined therapy with angiotensine converting enzyme inhibitors 
(ACEI) and angiotensin receptor blockers (ARB).4, 5 
 
In patients with ADPKD the glomerular filtration rate (GFR) remains stable for decades 
because of compensatory mechanisms.6 By the time renal function starts to decline, the 
kidneys are usually massively enlarged, and little normal renal parenchyma is recognizable on 
imaging studies. Thus early intervention in ADPKD promises more therapeutic benefit than 
late treatment, as cysts have not yet replaced the bulk of intact renal parenchyma and renal 
function is still maintained.4, 6, 7 
 
The analysis of sequential magnetic resonance imaging (MRI) or computed tomography (CT) 
scans can be used to monitor the rate of kidney volume enlargement in ADPKD.8 To identify 
rapidly the potential therapeutic benefit of a future treatment it is necessary to establish 
standardized imaging techniques and volumetric methods, which reliably detect kidney 
volume changes within a short time interval. 
 
We have prospectively evaluated 100 young ADPKD patients with preserved renal function 
by two serial MRI volume determinations within an interval of 6 months. We hypothesized 
that a manual segmentation volumetry method applied to MRI scans which were obtained 
with an optimized T1-weighted acquisition protocol without administration of gadolinium-
based MR contrast agents (GBCA) would be accurate and reliable to assess kidney volume 
change within 6 months.  
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Results 
Patient characteristics 
A total of 100 Caucasian ADPKD patients were studied. 97 patients had a positive family 
history for ADPKD. The demographic and clinical data of all patients are summarized in 
Table 1. The diagnosis of ADPKD was established in 89 patients prior to study inclusion at 
the age of 23.3±7.9 years. 25% of these patients had ADPKD related symptoms at the time of 
diagnosis. In 11 patients, the diagnosis of ADPKD was established at screening for study 
inclusion. At study inclusion, 47 patients reported ADPKD-related symptoms, including 
recurrent flank pain, episodes of macrohematuria and cyst infections. During follow up, 74 
patients were asymptomatic, 25 experienced flank pain, three macrohematuria and one patient 
had a cyst infection. Two-thirds of the patients had hypertension, mostly treated with 
angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). 
The baseline estimated creatinine clearance amounted to 109.8±25.5 ml/min (98.2±18.5 
ml/min/1.73m2) and the urinary albumin/creatinine ratio was 3.86±8.74 mg/mmol; both 
parameters remained unchanged during the 6-month follow up (108.4±24.7 ml/min and 
3.08±3.59 mg/mmol at month 6; P=0.259 and P=0.497 respectively). Microalbuminuria was 
present in 25 patients and only two patients had macroalbuminuria. 
 
Kidney and cyst volume changes within 6 months 
MRI volumetry-based volumes of both kidneys of all 100 ADPKD patients were assessed 
twice within 192±15 days. Figure 1A displays the total kidney volume (TKV) at baseline and 
at month 6 in all patients as a function of their age. The mean TKV amounted to 1003±568 
cm3 at baseline and increased significantly to 1034±602 cm3 (P<0.001). The mean TKV 
change was 31.8±72.0 cm3 (2.71±4.82%). This measured kidney volume increase in 6 months 
corresponded to an extrapolated value of 62.2±136.5 cm3 (5.36±9.47%) per year.  
 
Figure 1B shows that TKV increased in most patients but decreased in some. A significant 
decrease of the renal volume (i.e. outside the 95%-confidence interval for the volume 
measurements) was found in 13 single kidneys of 10 patients. Their MR images were 
reviewed in detail. In 6 patients (7 single kidneys), the volume decrease could be attributed to 
the rupture of one or few large cysts. These 6 patients were all male, had significantly higher 
TKV (1445±435 vs. 982±568 cm3; P=0.034) and reported more symptoms at baseline 
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(recurrent flank pain in 100% vs. 32%, episodes of macrohematuria in 83% vs. 16%, cyst or 
urinary tract infections in 33% vs. 12% and hypertension in 100% vs. 65%), whereas the age 
was similar compared to the remainder of the cohort (33.4±7.6 vs. 31.1±6.4 y; P=0.384). Only 
two of these 6 patients reported flank pain and none had macrohematuria during follow up. 
Figure 2 shows an example for the rupture of a large cyst at the lower pole of the left kidney 
between baseline and follow-up.  
 
The mean left kidney volume was higher than the right (530±301 vs. 480±284 cm3, P<0.001), 
whereas the growth rate did not differ significantly (2.50±5.48 vs. 2.80±5.14%, P=0.509). 
Figure 3A shows that the baseline volumes of the right and left kidney were highly correlated 
in individual patients (r=0.905, P<0.001). Furthermore Figure 3B reveals that their growth 
rates were also correlated (r=0.702, P<0.001). When 6 patients with documented cyst rupture 
were excluded, the correlation of the growth rates of the right and left kidney increased 
(r=0.818, P<0.001). 
 
Using T2-weighted MRI volumetry we also determined total cyst volume (TCV). TCV was 
476±440 cm3 at baseline and increased by 32.8±92.5 cm3 (5.45±14.28%) to 509±490 cm3 
(P<0.001). The change in TCV was directly correlated with the change in TKV (r=0.780, 
P<0.001). The mean noncystic renal volume (i.e. total kidney volume minus total cystic 
volume) at baseline was 527±183 cm3 and did not change during follow up (526±187 cm3, 
P=0.867).  
 
To assess the association between growth rate and kidney volume, the patients were stratified 
into three subgroups according to their kidney volume and the volume subgroups were further 
stratified by age (Table 2). 6 patients who exhibited a significant volume loss due to a cyst 
rupture and two patients with unilateral renal agenesis were excluded from this analysis. The 
proportion of young patients declines with increasing TKV, reflecting that TKV increased 
with age. There was a positive correlation between TKV and TKV change in both age 
subgroups (r=0.588, P<0.001 and r=0.612, P<0.001 for age <30 yr and >30 yr, respectively) 
and in the subgroups of higher age also the percentage TKV change correlated with TKV 
(r=0.080, P=0.639 for age <30yr and r=0.485, P<0.001 for age >30 yr). The TKV change was 
inversely correlated with age in most TKV subgroups. For the correlation of absolute and 
percentage TKV change with age, the coefficients are r=-0.379, P=0.013 and  r=-0.418, 
P=0.006 in patients with TKV 750ml;  r=-0.308, P=0.076 and  r=-0.360, P=0.036 in patients 
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with TKV 750-1500ml; r=-0.143, P=0.597 and  r=-0.165, P=0.541  in patients with 
TKV>1500 ml. The percentage but not absolute kidney volume progression was also 
inversely correlated with age in the whole cohort (r=–0.242; P=0.020 and r=0.015; P=0.891, 
respectively). 
 
Reproducibility of MRI kidney volumetry 
The comparison of single kidney volume (SKV) measurements for observer 1 (D.P.) and 2 
(F.K.) are shown as Lin’s concordance correlation plot in Figure 4. The concordance 
correlation coefficients (95% CI) were 1.000 (0.999-1.000) for intraobserver and 0.996 
(0.995-0.999) for interobserver correlations, representing excellent agreement. The coefficient 
increases in value as a function of the nearness of the data to the line of perfect concordance 
(accuracy) and the tightness of the data around this axis (precision). Accuracy and precision 
was high over the entire range of measured kidney volumes, indicating that there is similar 
reliability in measuring lower and higher SKV. 
 
Table 3 shows the measurement error, expressed as the within-subject standard deviation (sw) 
for intraobserver and interobserver duplicate measurements. The measurement error was 
similar over the entire range of kidney volumes (τ=0.139, P=0.163 and τ=0.142, P=0.155 for 
intraobserver and interobserver measurement error, respectively). The difference between an 
observer's measurement and the true kidney volume would be expected to be less than 1.96sw 
for 95% of measurements. Thus, the 95% confidence interval for SKV measurements as 
calculated based on the interobserver sw is ±15.687 cm3 and therefore lower than the mean 
positive or negative SKV change of ±25.3 cm3 during follow up.  
 
For single kidney cyst volume (SCV) measurements, the concordance correlation coefficients 
and the within subjects standard deviations for duplicate measurements (sw) are shown in table 
3. 
 
Correlation between renal volume and clinical variables 
Male patients had larger renal volumes than female (TKV 1158±555 cm3 vs. 738±493 cm3, 
P<0.001). TKV was also higher in patients with arterial hypertension compared to 
normotensives (1190±581 vs. 622±277 cm3, P<0.001) and in patients who reported previous 
episodes of hematuria (1399±581 vs. 904±522 cm3, P<0.001) and it was positively associated 
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with albuminuria (r=0.424, P<0.001) and negatively associated with creatinine clearance (r=–
0.348, P<0.001). These associations remained significant after normalisation of TKV for 
body surface area (BSA) and adjustment for age (for the association of TKV with gender 
P=0.004, hypertension P<0.001, hematuria P<0.001, creatinine clearance P=0.002 and 
albuminuria P<0.001). 
 
To identify risk factors for accelerated progression, the percentage kidney volume change was 
correlated with clinical and demographical variables. Patients with documented cyst rupture 
or unilateral renal agenesis were excluded from this analysis. Male patients tended to have 
higher growth rates than female, but this difference was not statistically significant 
(3.24±5.07% vs. 2.25±4.43%, P=0.339). Albuminuria was positively associated with volume 
growth rate (r=0.298, P=0.005). This association remained significant after adjusting for sex, 
age, diagnosis of hypertension, use of ACEI / ARBs, systolic blood pressure, creatinine 
clearance, TKV at baseline and the interval between the two MRI acquisitions (P=0.041).  
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Discussion 
The results of the present study demonstrate that an unenhanced MRI technique combined 
with manual segmentation volumetry can provide reproducible measures of renal volumes 
useful for monitoring changes that occur in early ADPKD within a short time interval.  
 
Various imaging modalities have been used to monitor volume progression in ADPKD, 
including sonography9, MRI8 and CT10-13. Sonography is highly operator dependent and lacks 
accuracy to detect small changes in renal volume.14 For safety reasons, MRI is favourable 
compared to CT technique as it avoids the radiation exposure and administration of iodinated 
contrast media. Previously, gadolinium-enhanced MRI has been used for renal volume 
determination in ADPKD patients.8 We used unenhanced MR image sequences only because 
GBCA have been associated with nephrogenic systemic fibrosis (NSF) in patients with renal 
disease.15, 16 Although NSF occurred predominantly in patients with GFR < 60 ml/min, the 
avoidance of GBCA is desirable for further studies in patients with ADPKD and impaired 
kidney function. Since the US food and drug administration (FDA) has raised concerns over 
using gadolinium in ADPKD patients, also the Consortium of Radiologic Imaging Studies of 
Polycystic Kidney Disease (CRISP; see below) has migrated to an unenhanced MRI protocol 
for further studies. 
 
Volume determination from MRI data requires a segmentation of MR images. An automated 
method would be desirable but is not easily applicable to polycystic kidneys because of their 
inhomogeneous structure. Semiautomated segmentation methods include region-based 
thresholding and stereology. In region-based thresholding an intensity threshold is set by a 
trained analyst for every image slice to differentiate the area of interest from surrounding 
tissue. This method is limited by the intrinsic spatial intensity fluctuation of MR images. The 
human visual system has the ability to overcome spatial intensity fluctuations and resolve 
small contrast differences and is probably most feasible for MR image segmentation. The 
stereological technique depends on the capability of an analyst to differentiate adjacent tissues 
and makes use of a grid superimposed on the image data, which facilitates volume 
determination but does not utilize the full resolution of image data.17, 18 We used a manual 
contour tracing method, which is more time consuming than semiautomated approaches but 
allows a very precise definition of organ boundaries utilizing the full resolution of MR data. 
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Manual segmentation is not applicable to cyst volume determination due to the large number 
of cysts. Thus we used a region-based thresholding method to determine cyst volumes. 
 
The question, if renal volume changes can be measured within a 6-months interval, depends 
on the magnitude of the measurement imprecision compared to the actual kidney volume 
change. The accuracy and reliability of renal volume measurements was mirrored by excellent 
concordance among all measurements as continuous variables, based on Lin’s concordance 
correlation coefficients of 1.000 and 0.996 for intra- and interobserver correlations. The 95% 
confidence interval for kidney volume measurements as calculated based on the interobserver 
variability was considerably lower than the true volume change. This applies for the entire 
range of measured kidney volumes as the measurement error was independent of the kidney 
volume. The high accuracy and reproducibility of our method thus allows monitoring changes 
that occur in early ADPKD within a short time interval. Cyst volume measurements were also 
reliable but the measurement error was larger compared to kidney volume measurements 
owing to the use of a region-based thresholding method instead of manual segmentation. 
 
The CRISP analyzed annual contrast-enhanced MRI over 3 years in 241 American ADPKD 
patients.8 The renal volume was measured in T1-weighted gadolinium-enhanced images with 
the use of a stereologic method. At baseline TKV amounted to 1076 cm3 and increased by 
63.4 cm3 or 5.27% per year. Using a manual segmentation technique we studied 100 
European ADPKD patients with similar baseline characteristics as the CRISP cohort. TKV 
increased by 31.8 cm3 within 6 months corresponding to a growth rate of 2.71%. Assuming an 
exponential growth kinetic with a constant growth rate, the calculated annual growth rate was 
5.36% in our cohort and hence very similar to the CRISP results. In further analogy to the 
CRISP data we could confirm the high degree of correlation between right and left renal 
volumes and their growth rates. Thus, we were able to confirm the CRISP results in an 
European ADPKD population. 
 
In 7 kidneys we identified the asymptomatic spontaneous rupture of large cysts, causing a 
significant reduction of the kidney volume. Cyst loss has been judged not to contribute 
appreciably to the renal growth kinetic over the long term.19 In the short term however, we 
could demonstrate that cyst ruptures can cause considerable reduction of renal volume. Thus, 
if volumetry data are used to monitor disease progression over a short time interval, 
complemented detailed image analysis can be helpful. 
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 The kidney volume enlargement in ADPKD has been suggested to follow an exponential 
characteristic with a growth rate that is patient specific and relatively constant over time.19 
Based on two measurements per patient, the growth characteristic can not be defined exactly. 
However, the correlation between TKV and TKV growth found in both age subgroups of our 
cohort supports the hypothesis of a patient specific growth rate. The percentage TKV change 
correlated with TKV only in patients > 30 years and the correlation between TKV and TKV 
growth gained strength with increasing patient age. It is clear, that the enlargement of the 
polycystic kidney is due to the growth of the cysts. With increasing age, cyst volume 
contributes proportionally more and more to total kidney volume. Hence, the rate of cyst 
growth will influence total renal volume more pronouncedly in advanced disease. As a 
consequence, total kidney volume in relation to age might serve as a prognostic marker in 
patients > 30 years but it seems to be less reliable in young patients. 
 
We found the percentage renal volume growth rate to be higher in young patients. Rather than 
reflecting an accelerated progression in these patients, this finding might be due to selection 
bias: young patients with mild disease were probably underrepresented in our cohort because 
the diagnosis was not yet established or they were not motivated for study participation by 
lack of symptoms. 
 
Renal volume in ADPKD has previously been correlated with other markers of advanced 
disease, such as hypertension, albuminuria and reduced GFR.20, 21 Previously identified risk 
factors for accelerated disease include male sex, gross hematuria, early onset of hypertension 
and proteinuria.9, 21-23 Our results are in line with these previous studies as total kidney 
volume at baseline was positively correlated with hypertension, hematuria and albuminuria 
and albuminuria was associated with accelerated volume progression. 
 
Taken together, the high reproducibility and accuracy of the measurements, the correlation of 
the volumetry results with clinically known progression markers and the accordance of our 
results with the CRISP data underscore the validity of our method to monitor changes in early 
ADPKD within an interval of 6 months. The method we describe here can be easily 
implemented into clinical practice as we relied on a standardized MRI acquisition protocol 
and commercially available FDA-approved volumetry software. These data may have 
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implications for designing future interventional trials and are important for examining the 
therapeutic benefit of ongoing clinical trials for this devastating disease. 
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Methods 
Patient population 
The subjects for this study were 100 participants of an ADPKD registry. The diagnosis of 
ADPKD was based on ultrasonographic diagnostic criteria in patients with a family history of 
ADPKD.24 In patients with a negative family history, proof of a disease causing mutation in 
the PKD1 gene was obtained by genetic testing (sequencing analysis by Athena Diagnostics, 
Inc., Worcester, MA, USA). As we also aimed to screen patients for a clinical trial, they 
generally fulfilled the inclusion criteria of that trial,25 most importantly age 18–40 years and  
estimated creatinine clearance ≥70 ml/min. Patients were studied at the University Hospital of 
Zürich, Switzerland between April 2005 and March 2008. The study was conducted according 
to the guidelines on Good Clinical Practice and the Declaration of Helsinki. Study approval 
was obtained from the local Ethics Committee, and all patients gave written, informed 
consent. 
 
Clinical evaluation and laboratory analyses 
After screening and enrolment, a detailed medical history was obtained, including ADPKD 
related symptoms, previous hospitalization and medication. Blood pressures were measured 
twice in each arm at every study visit in sitting position after a rest of 5 minutes, using an 
oscillometric blood pressure monitor (Boso-Medicus, Jungingen, Germany). The lower of the 
two consecutive measurements in the arm with the higher blood pressure was used for 
analysis. Arterial hypertension was defined as systolic blood pressure ≥140 mmHg or 
diastolic blood pressure ≥90 mmHg at all three study visits (screening, baseline and month 6), 
or treatment with an antihypertensive drug. Blood samples were obtained at month 0 and 6 for 
the determination of serum creatinine (IDMS traceable modified Jaffé method). Creatinine 
clearance was estimated according to the Cockcroft-Gault formula. The spot urine was 
analyzed for the ratio of albumin to creatinine (mg/mmol).  
 
Magnetic resonance imaging 
All subjects underwent a standardized MRI protocol at month 0 and 6 using an 1.5 Tesla 
scanner (Signa EchoSpeed EXCITE® HD or HDx, GE Healthcare, Waukesha, Wisconsin, 
USA), as described elsewhere.25 Briefly, for signal reception in all examinations an 8-channel 
anteroposterior phased-array surface coil was placed around the patient covering the entire 
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kidneys. The imaging protocol included unenhanced sequences only. After obtaining a 
localizer sequence a coronal single shot fast spin echo (SSFSE) sequence (TR msec/TE msec 
1349/90.1; field of view, 48x48 cm; acquisition matrix, 384x224; section thickness, 4 mm; no 
interslice gap) was acquired in breathhold technique to obtain an overview of the extent of the 
cystic disease of the patient. Based on this coronal sequence the transaxial sequences were 
planned. The transaxial sequences consisted of two breathhold T1-weighted fast spoiled 
gradient echo (FSPGR) sequences (TR msec/TE msec=85/1.4, flip angle, 70°) with 3 and 4 
mm slice thicknesses and no interslice gap. Sequences with 4 mm slice thickness were only 
assessed if 3 mm sequences were not analyzable due to artefacts or insufficient coverage of 
the volume of interest. In addition a transaxial T2-weighted fast spin echo (FSE) sequence 
with respiratory triggering was performed (TR msec/TE msec=17143/102.8) with 3 mm slice 
thickness and no interslice gap. 
 
Renal volume measurements 
Kidney volumes were measured by manually tracing the kidney contours using volume 
analysis software implemented on an Advantage Windows workstation (4.4., GE Healthcare, 
Buc, France). The renal volume was calculated for each kidney by multiplying all outlined 
areas by the section thickness and summing the volume of each section. Non-kidney 
parenchyma, e.g. renal hilus, was identified by checking adjacent slides if needed and 
excluded from the measurement. For measurements of the total kidney volumes the T1-
weighted FSPGR sequences were used. 
 
For the determination of cyst volumes a region-based thresholding technique was applied to 
the axial T2-weighted FSE sequences. In this sequence the cysts appear brighter than the renal 
parenchyma. The cyst volume was determined using a region-based thresholding technique. 
An intensity threshold was selected on every image slice by an analyst. The volume of all 
cysts was calculated for each kidney by multiplying cyst areas by the section thickness and 
summing the volume of each section. These measurements were also performed using the 
Advantage Windows workstation. 
 
Individual kidneys were measured in cm3 and the values of the right and left kidney were 
added to calculate the total kidney volume (TKV) and the total cyst volume (TCV) for each 
patient. The annual change in kidney volume was determined for each patient assuming an 
exponential growth.19 
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 The measurements of total kidney and cyst volumes were performed by two observers (D.P. 
and F.K.) which have been trained by a radiologist and have performed their first 
measurements under supervision. Depending on the kidney size, analysis time was 15–45 
minutes for one single kidney volume determination, while cyst volume measurement 
required 10–25 minutes per kidney. For the assessment of the intraobserver agreement of 
kidney volume determination, one of the observers (D.P.) repeated 48 single kidney volume 
(SKV) measurements at a different occasion. To further validate the measurements, a second 
independent observer (F.K.) repeated the measurements and interobserver agreement was 
determined. Repeated measurements were performed without knowledge of the results of 
prior measurements or each other's results. 
 
Statistical analysis 
Results are expressed as means±SD. Means of continuous data were compared by Student’s t 
test. All P values were two sided for the comparison with the baseline values, and those less 
than 0.05 were considered statistically significant. The Pearson correlation coefficient was 
used to test for associations between continuous variables. TKV and albumin/creatinine ratio 
variables were log-transformed to achieve a normal distribution for parametric tests. 
Multivariate linear regression was used to determine independent predictors of growth rate 
and to adjust TKV for age in the comparison among patients with different clinical 
characteristics. 
 
Intraobserver and interobserver agreement of the kidney volumetry was evaluated by 
computing Lin's concordance correlation coefficient (ρ-c) for each comparison.26 In addition, 
the within-subject standard deviation was calculated to assess the reproducibility of kidney 
and cyst volume measurement.27 The Kendall tau rank correlation coefficient between the 
standard deviation and the mean of replicate measurements was used to test whether the 
measurement error was proportional to the volume measured. 
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Tables 
 
Table 1 
 
Demographic and clinical data at baseline in 100 ADPKD patients. 
 
  
Demographic characteristics  
Age (years) 31.2 ± 6.4 
Sex (female ; male) 37 ; 63 
Family history of ADPKD 97  
BMI (kg/m2) 24.3 ± 3.8 
SBP / DBD (mm Hg) 133.9 ± 16.5 / 84.8 ± 10.6 
Current smoker 36  
  
Symptoms and complications of ADPKD  
Hypertension 67  
Antihypertensive treatment 41  
ACEi and/or ARB therapy 39  
Recurrent flank pain 36  
History of macrohematuria 20  
History of cyst infections 13  
History of intracranial bleeding 2  
  
Renal parameters  
Serum creatinine (µmol/l) 90.2 ± 19.1 
Estimated creatinine clearance (C-G; ml/min) 109.8 ± 25.5 
 
Data represents mean (SD) or the number of patients. BMI, body mass index; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; ACEi, angiotensin-converting enzyme 
inhibitor; ARB, angiotensin receptor blocker; C-G, Cockcroft-Gault. 
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Table 2 
 
Relationship between age, total kidney volume, volume progression and creatinine 
clearance. 
 
  Total Kidney Volume Estimated creatinine 
clearance 
Total kidney volume and 
age group 
N At baseline 
ml 
Change 
ml 
Change 
% 
At baseline 
ml/min 
Change 
ml/min 
<750 ml and <30 yr 23 544±126 18.5±24.8 2.79±4.81 120±27 -0.9±15.1 
<750 ml and ≥30 yr 18 530±149 1.2±17.0 0.06±4.06 100±22 -0.4±10.1 
750-1500 ml and <30 yr 11 1016±198 39.2±24.6 4.60±2.60 126±26 -2.6±8.7 
750-1500 ml and ≥30 yr 23 1054±156 24.9±46.0 2.52±4.31 109±26 -2.7±14.1 
>1500 ml and <30 yr 2 1857±261 112.6±38.1 6.16±1.30 116±2 13.3±21.3* 
>1500 ml and ≥30 yr 14 2043±386 123.7±118.2 5.94±4.06 100±16 -3.2±9.4 
 
 
Data represents mean (SD)  
*The apparent improvement of creatinine clearance is due to a 15 kg weight gain during 
follow up of one of these two patients affecting the estimate of creatinine clearance according 
to the Cockcroft-Gault formula. 
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Table 3 
 
Intraobserver and interobserver agreement of kidney volumetry measurements.  
 
Comparison 
N = 48 
Lin’s concordance 
correlation coefficient 
ρ_c (95% CI) 
Within-subject 
standard deviation 
sw, cm3 
Kidney volume   
Observer 1 vs. 1 
 
1.000 (0.999-1.000) 
P < 0.001 
6.130 
Observer 1 vs. 2 
 
0.996 (0.995-0.999) 
P < 0.001 
8.003 
   
Cyst volume   
Observer 1 vs. 1 0.993 (0.989-0.997) 
P < 0.001 
9.8387 
Observer 1 vs. 2 0.943 (0.918-0.969) 
P < 0.001 
25.500 
 
Comparison of single kidney volume and cyst volume of single kidney measurements by 2 
observers. 
 
 
 
Figures 
Figure 1 
 
A) Total kidney volume (TKV) progression within 6 months in relation to age in 100 
individual ADPKD patients (female in red, male in blue). B) TKV change (ΔTKV) of 
individual patients lined up in ascending order.  
Figure 2 
 
 
 
 
 
 
 
 
 
 
**
A B
 
Coronal T2-weighted MRI sections reveal the rupture of a large cyst. A) At month 0 a large 
cyst (**) at the lower pole of the left kidney is seen. B) The large lower left pole cyst has 
disappeared at month 6. In the 6-month observation period the right kidney volume increased 
by 44 cm3 whereas the left kidney volume decreased by 59 cm3 and hence total kidney 
volume was reduced by 15 cm3 within 6 months. 
 2
Figure 3 
 
 
A) High correlation between left and right kidney volumes at baseline (r = 0.905, P < 0.001) 
and B) between TKV change (ΔTKV) of the left and right kidney over 6 months in 100 
patients (r = 0.702, P < 0.001). The correlation between ΔTKV of the right and left kidney 
 3
increased after the exclusion of patients with documented cyst rupture (r = 0.818, P < 0.001). 
Symbols represent individual patients, stars patients with documented cyst rupture (n=6). 
Lines of linear regression with 95% confidence interval are shown. 
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Figure 4 
 
 
 
 
Lin’s concordance correlation plots demonstrating high degree of agreement between 
repeated measurements of observer 1 (n = 48; A) and between measurements of observer 1 
and 2 (n = 48; B). All measurements are in cm3. SKV, single kidney volume. 
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